medigraphic.com

2022, Number 2

<< Back Next >>

Rev Cuba Endoc 2022; 33 (2)

Antimullerian hormone and polycystic ovary syndrome

Monteagudo PG, Álvarez ÁA, Ovies CG, Gómez AM, Cabrera GM

Language: Spanish
References: 55
Page:
PDF size: 221.61 Kb.


ABSTRACT

Introduction: The diagnosis of polycystic ovary syndrome, due to its great phenotypic diversity, has been and is the subject of debate. It is in this context that in recent years the measurement of anti-Müllerian hormone has been proposed as a more effective indicator in the evaluation of follicular dysfunction.
Objective: Compile information on the antimullerian hormone and its diagnostic utility in polycystic ovary syndrome.
Methods: Bibliographic review of 57 articles obtained from the Google Scholar, Medline and Pubmed databases.
Conclusions: The intrafollicular concentration of anti-Müllerian hormone is inversely proportional to the size of the ovarian follicle and its serum levels are proportional to the reserve of follicles in the preantral or small antral stage. An increase in anti-Müllerian hormone has been observed in women with polycystic ovary syndrome, which is believed to play a role in the pathogenesis of abnormal folliculogenesis and ovarian dysfunction. For this reason, the determination of anti-Müllerian hormone has been used for diagnostic purposes, as an indicator of follicular reserve or as a predictor of response to treatment. However, the technical difficulties for the measurement and the population and inter-individual variability have meant that its practical utility for the diagnosis of polycystic ovary syndrome has not been consistently established.


REFERENCES

  1. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health. 2018;15(11):2589. DOI: https://doi.org/10.3390/ijerph151125891.

  2. Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018;132(2):321-336. DOI: https://doi.org/10.1097/AOG.00000000000026982.

  3. McCartney CR, Marshall JC. Clinical practice. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54-64. DOI: https://doi.org/10.1056/NEJMcp15149163.

  4. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 [acceso: 28/12/2021];2:16057. Disponible en: https://www.nature.com/articles/nrdp2016574.

  5. Pasquali R. Contemporary approaches to the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2018;9(4):123-34. DOI: https://doi.org/10.1177/20420188187567905.

  6. Rocha AL, Oliveira FR, Azevedo RC, Silva VA, Peres TM, Candido AL, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8:565. DOI: https://doi.org/10.12688/f1000research.15318.16.

  7. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;106(6):1510-20. DOI: https://doi.org/10.1016/j.fertnstert.2016.07.11217.

  8. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic Ovary Syndrome, a modern epidemic: An overview. JDDT. 2019 [acceso: 28/12/2021];9(3):641-4. Disponible en: http://jddtonline.info/index.php/jddt/article/view/26618.

  9. Popescu I, Ionescu C, Dimitriu M, Bohîl?ea R, Viezuina R, Davitoiu B, et al. Controversies in polycystic ovarian syndrome. Gineco. 2017 [acceso: 28/12/2021];13:42-5. Disponible en: http://gineco.eu/system/revista/37/42-45.pdf9.

  10. Sujata K, Swoyam S. 2D and 3D Trans-vaginal Sonography to Determine Cut-offs for Ovarian Volume and Follicle Number per Ovary for Diagnosis of Polycystic Ovary Syndrome in Indian Women. J Reprod Infertil. 2018 [acceso: 28/12/2021];19(3):146-51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104427/10.

  11. Christ JP, Vanden Brink H, Brooks ED, Pierson RA, Chizen DR, Lujan ME. Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome. Fertil Steril. 2015;103(3):787-94. DOI: https://doi.org/10.1016/j.fertnstert.2014.12.09411.

  12. Tam M, Le MT, Le VN, Le DD, Nguyen VQ, Chen C, et al. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Offo). 2019;90(4):579-85. DOI: https://doi.org/10.1111/cen.1393412.

  13. Singh AK, Singh R. Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocr Metab. 2015 [acceso: 28/12/2021];19(6):731-43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673800/13.

  14. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370-85. DOI: https://doi.org/10.1093/humupd/dmt06214.

  15. McLennan IS, Pankhurst MW. Anti-Müllerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. J Endocrinol. 2015;226(3):R45-57. DOI: https://doi.org/10.1530/JOE-15-020615.

  16. Edelsztein NY, Grinspon RP, Schteingart HF, Rey RA. Anti-Müllerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol. 2016;2016:20. DOI: https://doi.org/10.1186/s13633-016-0038-216.

  17. Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 2017;471:248-53. DOI: https://doi.org/10.1016/j.cca.2017.06.00917.

  18. Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055. DOI: https://doi.org/10.1038/ncomms1005518.

  19. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223-7. DOI: https://doi.org/10.1093/humrep/del16519.

  20. Vigier B, Picard JY, Tran D, Legeai L, Josso N. Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology. 1984;114(4):1315-20. DOI: https://doi.org/10.1210/endo-114-4-131520.

  21. Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011;96(5):1246-51. DOI: https://doi.org/10.1016/j.fertnstert.2011.08.01521.

  22. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891-9. DOI: https://doi.org/10.1210/endo.142.11.848622.

  23. Xu J, Bishop CV, Lawson MS, Park BS, Xu F. Anti-Müllerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. Hum Reprod. 2016;31(7):1522-30. DOI: https://doi.org/10.1093/humrep/dew10023.

  24. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21(12):3103-7. DOI: https://doi.org/10.1093/humrep/del29124.

  25. Pankhurst MW, Mc Lennan IS. Human blood contains both the uncleaved precursor of anti-Mullerian hormone and a complex of the NH2- and COOH-terminal peptides. Am J Physiol Endocrinol Metab. 2013;305(10):E1241-7. DOI: https://doi.org/10.1152/ajpendo.00395.201325. . [ Links ]

  26. Dilaver N, Pellatt L, Jameson E, Ogunjimi M, Bano G, Homburg R, et al. The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome. Hum Reprod. 2019;34(12):2467-79. DOI: https://doi.org/10.1093/humrep/dez21426.

  27. Qi X, Pang Y, Qiao J. The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;199:82-7. DOI: https://doi.org/10.1016/j.ejogrb.2016.01.02927.

  28. Oh SR, Choe SY, Cho YJ. Clinical application of serum anti-Müllerian hormone in women. Clin Exp Reprod Med. 2019;46(2):50-9. DOI: https://doi.org/10.5653/cerm.2019.46.2.5028.

  29. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98(8):3332-40. DOI: https://doi.org/10.1210/jc.2013-139329.

  30. Liu XY, Yang YJ, Tang CL, Wang K, Chen JJ, Teng XM, et al. Elevation of antimüllerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. Fertil Steril. 2019;111(1):157-67. DOI: https://doi.org/10.1016/j.fertnstert.2018.09.02230.

  31. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers. 2016;2016:5246217. DOI: https://doi.org/10.1155/2016/524621731.

  32. Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, et al. Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines. Trends Endocrinol Metab. 2019;30(7):467-78. DOI: https://doi.org/10.1016/j.tem.2019.04.00632.

  33. Han X, McShane M, Sahertian R, White C, Ledger W. Pre-mixing serum samples with assay buffer is a prerequisite for reproducible anti-Mullerian hormone measurement using the Beckman Coulter Gen II assay. Hum Reprod. 2014;29(5):1042-8. DOI: https://doi.org/10.1093/humrep/deu05033.

  34. Rustamov O, Smith A, Roberts SA, Yates AP, Fitzgerald C, Krishnan M, et al. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod. 2012;27(10):3085-91. DOI: https://doi.org/10.1093/humrep/des26034.

  35. Seifer DB, Golub ET, Lambert G, Benning L, Anastos K, Watts DH, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril. 2009;92(5):1674-8. DOI: https://doi.org/10.1016/j.fertnstert.2008.08.11035.

  36. Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve. Int J Endocrinol. 2013;2013:818912. DOI: https://doi.org/10.1155/2013/81891236.

  37. Meczekalski B, Czyzyk A, Kunicki M, Podfigurna A, Plociennik L, Jakiel G, et al. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest. 2016;39(11):1259-65. DOI: https://doi.org/10.1007/s40618-016-0497-637.

  38. Pankhurst MW. A putative role for anti-Müllerian hormone (AMH) in optimising ovarian reserve expenditure. J Endocrinol. 2017;233(1):R1-R13. DOI: https://doi.org/10.1530/JOE-16-052238.

  39. Lebkowska A, Kowalska I. Anti-Müllerian hormone and polycystic ovary syndrome. Endokrynol Pol. 2017;68(1):74-8. DOI: https://doi.org/10.5603/EP.a2016.006539.

  40. Bhide P, Homburg R. Anti-Müllerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:38-45. DOI: https://doi.org/10.1016/j.bpobgyn.2016.03.00440.

  41. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004;82(4):970-2. DOI: https://doi.org/10.1016/j.fertnstert.2004.06.00141.

  42. Dewailly D, Barbotin AL, Dumont A, Catteau S, Robin G. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2020;11:641. DOI: https://doi.org/10.3389/fendo.2020.0064142.

  43. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau S. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22(6):709-24. DOI: https://doi.org/10.1093/humupd/dmw02743.

  44. Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18(2):323-7. DOI: https://doi.org/10.1093/humrep/deg04244.

  45. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118-21. DOI: https://doi.org/10.1016/j.fertnstert.2009.11.00245.

  46. Li L, Chen X, Mo Y, Chen Y, Wenig M, Yang D. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17-18):519-24. DOI: https://doi.org/10.1007/s00508-010-1426-x46.

  47. Sopher AB, Grigoriev G, Laura D, Cameo T, Lerner JP, Chang RJ, et al. Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. J Pediatr Endocrinol Metab. 2014;27(11-12):1175-9. DOI: https://doi.org/10.1515/jpem-2014-012847.

  48. Carmina E, Fruzzetti F, Lobo RA. Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea. Am J Obstet Gynecol. 2016;214(6):714.e1-6. DOI: https://doi.org/10.1016/j.ajog.2015.12.05548.

  49. Eldar T, Margalioth EJ, Gal M, Ben A, Algur N, Zylber E, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005;20(7):1814-9. DOI: https://doi.org/10.1093/humrep/deh87349.

  50. Xi W, Yang Y, Mao H, Zhao X, Liu M, Fu S. Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome. J Ovarian Res. 2016;9:3. DOI: https://doi.org/10.1186/s13048-016-0214-250.

  51. Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016;32(5):503-12. DOI: https://doi.org/10.1016/j.rbmo.2016.01.01051.

  52. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14(4):367-78. DOI: https://doi.org/10.1093/humupd/dmn01552.

  53. Fonseca HP, Brondi RS, Piovesan FX, Miklos TG, Aldrighi JM. Anti-Mullerian hormone and insulin resistance in polycystic ovary syndrome. Gynecol Endocrinol. 2014;30(9):667-70. DOI: https://doi.org/10.3109/09513590.2014.92000453.

  54. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010;139(5):825-33. DOI: https://doi.org/10.1530/REP-09-041554.

  55. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89(1):318-23. DOI: https://doi.org/10.1210/jc.2003-03093255.




2020     |     www.medigraphic.com